Is Litfulo Approved for Alopecia?
No, Litfulo (ritlecitinib) is not approved for alopecia areata or any form of alopecia. The FDA approved it in June 2023 for treating active non-segmental vitiligo in adults and children 12 years and older.[1] It targets Janus kinase 3 (JAK3) and tyrosine kinase 2 (TYK2) to reduce inflammation in autoimmune skin conditions.
What Is Litfulo Actually Used For?
Litfulo treats non-segmental vitiligo, a condition causing white patches on the skin due to melanocyte loss. It's taken as a 50 mg oral capsule once daily. Clinical trials showed 21-30% of patients achieving at least 75% improvement in facial vitiligo after 6-12 months, compared to 3-10% on placebo.[1][2]
Why the Confusion with Alopecia?
Both vitiligo and alopecia areata are autoimmune diseases, and JAK inhibitors like Litfulo have shown efficacy in alopecia trials. Ritlecitinib met its primary endpoint in Pfizer's ALLEGRO phase 2b/3 trial, with 23-36% of patients achieving 80% scalp hair coverage after 24 weeks at higher doses.[3] Pfizer submitted an sNDA to the FDA for alopecia areata in 2022, but approval has not occurred as of late 2024. Olumiant (baricitinib), another JAK inhibitor, is the only FDA-approved drug for severe alopecia areata since 2022.
When Might Litfulo Be Approved for Alopecia?
No timeline exists for alopecia approval. Pfizer prioritizes vitiligo, and regulatory delays or additional data needs could push any decision past 2025. Off-label use for alopecia occurs in some dermatology practices based on trial data, but this lacks FDA backing and insurance coverage.[4]
Alternatives for Alopecia Areata Treatment
- FDA-approved: Olumiant (baricitinib, 4 mg daily) for severe cases in adults.
- Other JAK inhibitors: deuruxolitinib (Leqselvi, approved 2024) for ages 12+.
- Topicals/systemics: Corticosteroids, minoxidil, or methotrexate for milder cases.
- Emerging: Ritlecitinib awaits approval; brepocitinib failed phase 3.
Consult a dermatologist for personalized options, as alopecia severity varies.
Patent and Availability Details
Litfulo holds U.S. patents until at least 2037, with pediatric exclusivity to 2041.[5] No generics expected soon.
[1]: FDA Approval Letter for Litfulo
[2]: Pfizer Litfulo Prescribing Information
[3]: New England Journal of Medicine - ALLEGRO Trial
[4]: American Academy of Dermatology Guidelines
[5]: DrugPatentWatch.com - Ritlecitinib Patents